Johnson & Johnson - JNJ Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $170.65
  • Forecasted Upside: 5.56%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 9 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▼ -1.25 (-0.77%)

This chart shows the closing price for JNJ by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Johnson & Johnson Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for JNJ and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for JNJ

Analyst Price Target is $170.65
▲ +5.56% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Johnson & Johnson in the last 3 months. The average price target is $170.65, with a high forecast of $215.00 and a low forecast of $52.00. The average price target represents a 5.56% upside from the last price of $161.66.

This chart shows the closing price for JNJ for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 14 investment analysts is to hold stock in Johnson & Johnson. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00Low
9/8/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$175.00 ➝ $158.00Low
9/6/2023HSBCInitiated CoverageHold$175.00Low
9/5/2023Raymond JamesLower TargetOutperform ➝ Outperform$184.00 ➝ $179.00Low
8/31/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$187.00 ➝ $172.00Low
8/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00Low
8/31/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$195.00 ➝ $186.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00Low
8/4/2023Atlantic SecuritiesBoost TargetNeutral ➝ Neutral$167.00 ➝ $170.00Low
7/31/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$215.00Low
7/24/2023BarclaysBoost TargetEqual Weight$171.00 ➝ $175.00Low
7/24/2023Raymond JamesBoost TargetOutperform$181.00 ➝ $184.00Low
7/21/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$187.00Low
7/21/2023JPMorgan Chase & Co.Boost TargetNeutral$175.00 ➝ $180.00Low
7/21/2023Stifel NicolausBoost Target$165.00 ➝ $175.00Low
7/21/2023Credit Suisse GroupBoost TargetNeutral$170.00 ➝ $175.00Low
5/30/2023CitigroupInitiated CoverageBuy$185.00Low
5/5/2023Credit Suisse GroupBoost Target$168.00 ➝ $170.00Low
4/19/2023Atlantic SecuritiesLower TargetNeutral$168.00 ➝ $167.00Low
4/19/2023Morgan StanleyBoost TargetEqual Weight$179.00 ➝ $183.00Low
4/19/2023Raymond JamesLower TargetOutperform$185.00 ➝ $181.00Low
4/10/2023Morgan StanleyLower TargetEqual Weight$180.00 ➝ $179.00Low
3/28/2023UBS GroupInitiated CoverageNeutral$164.00Low
2/28/2023GuggenheimInitiated CoverageNeutral$161.00Low
2/6/2023Piper SandlerLower Target$55.00 ➝ $52.00Low
2/1/2023Cantor FitzgeraldReiterated RatingOverweight$215.00Low
1/25/2023Atlantic SecuritiesBoost TargetNeutral$160.00 ➝ $168.00Low
1/25/2023Morgan StanleyBoost TargetEqual Weight$176.00 ➝ $180.00Low
1/20/2023SVB LeerinkLower TargetOutperform$194.00 ➝ $186.00Low
12/12/2022CitigroupBoost TargetBuy$198.00 ➝ $205.00Low
12/6/2022Morgan StanleyLower TargetEqual Weight$178.00 ➝ $176.00Low
12/1/2022Morgan StanleyBoost Target$170.00 ➝ $178.00Low
11/17/2022Credit Suisse GroupInitiated CoverageNeutral$170.00Low
10/19/2022Atlantic SecuritiesLower TargetNeutral$165.00 ➝ $160.00Low
10/19/2022Raymond JamesLower TargetOutperform$192.00 ➝ $185.00Low
10/19/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $170.00Low
10/19/2022Sanford C. BernsteinLower Target$194.00 ➝ $190.00Low
10/17/2022BarclaysInitiated CoverageEqual Weight$175.00Low
10/14/2022Bank of AmericaLower TargetNeutral$185.00 ➝ $178.00Low
10/12/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00Low
10/5/2022CitigroupLower Target$201.00 ➝ $198.00Low
9/12/2022Morgan StanleyLower TargetEqual Weight$174.00 ➝ $173.00Low
7/21/2022UBS GroupLower Target$185.00 ➝ $180.00Low
7/20/2022SVB LeerinkLower Target$200.00 ➝ $194.00Low
7/20/2022CitigroupLower Target$205.00 ➝ $201.00Low
7/13/2022Wells Fargo & CompanyBoost TargetOverweight$190.00 ➝ $195.00N/A
7/8/2022Morgan StanleyBoost TargetEqual Weight$173.00 ➝ $174.00N/A
6/22/2022Daiwa Capital MarketsInitiated CoverageOutperformLow
5/17/2022CitigroupLower Target$210.00 ➝ $205.00N/A
4/20/2022Raymond JamesBoost TargetOutperform$195.00 ➝ $196.00Low
4/20/2022Credit Suisse GroupBoost TargetOutperform$200.00 ➝ $205.00Low
4/20/2022CitigroupBoost TargetBuy$203.00 ➝ $210.00Low
4/14/2022Raymond JamesBoost TargetOutperform$185.00 ➝ $195.00Low
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$163.00 ➝ $181.00Low
4/6/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $173.00High
3/16/2022Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$180.00 ➝ $183.00Low
3/2/2022Bank of AmericaInitiated CoverageNeutral ➝ NeutralLow
1/26/2022Raymond JamesBoost Target$178.00 ➝ $185.00Low
1/24/2022Morgan StanleyLower TargetEqual Weight$187.00 ➝ $175.00Medium
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$161.00High
12/15/2021CitigroupReiterated RatingBuy ➝ Buy$192.00 ➝ $195.00Low
10/20/2021Raymond JamesLower TargetOutperform$183.00 ➝ $178.00Low
10/7/2021Wells Fargo & CompanyReiterated RatingBuyLow
9/7/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$187.00Medium
7/29/2021SVB LeerinkReiterated RatingBuyLow
7/21/2021SVB LeerinkReiterated RatingOutperformLow
6/7/2021Credit Suisse GroupSet TargetBuy$193.00Low
6/1/2021Credit Suisse GroupSet TargetBuy$193.00High
5/28/2021Morgan StanleyInitiated CoverageOverweight$187.00Low
1/27/2021JPMorgan Chase & Co.Boost TargetNeutral$157.00 ➝ $175.00Medium
1/27/2021Credit Suisse GroupBoost TargetOutperform$168.00 ➝ $193.00Medium
1/27/2021Raymond JamesBoost TargetOutperform$158.00 ➝ $183.00Medium
1/27/2021CowenBoost TargetOutperform$170.00 ➝ $195.00Medium
1/27/2021Morgan StanleyBoost TargetOverweight$178.00 ➝ $187.00Medium
1/27/2021SVB LeerinkBoost TargetOutperform$180.00 ➝ $200.00Medium
1/27/2021Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$175.00 ➝ $190.00Medium
1/26/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$180.00 ➝ $200.00Medium
12/15/2020Morgan StanleyBoost TargetOverweight$170.00 ➝ $178.00Low
11/20/2020Raymond JamesReiterated RatingBuyMedium
10/14/2020Credit Suisse GroupBoost TargetPositive ➝ Outperform$163.00 ➝ $168.00Low
10/14/2020Cantor FitzgeraldBoost TargetPositive ➝ Overweight$168.00 ➝ $180.00Low
10/13/2020Credit Suisse GroupSet TargetBuy$163.00Low
9/4/2020Credit Suisse GroupReiterated RatingBuyMedium
8/19/2020Stifel NicolausDowngradeBuy ➝ HoldLow
8/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
7/20/2020Bank of AmericaReiterated RatingBuyLow
7/20/2020Independent ResearchUpgradeHold ➝ Buy$161.00 ➝ $164.00Low
7/17/2020Raymond JamesBoost TargetOutperform$157.00 ➝ $158.00Medium
7/17/2020CitigroupBoost TargetBuy$165.00 ➝ $170.00Low
7/15/2020SVB LeerinkReiterated RatingOutperformMedium
4/29/2020Morgan StanleyBoost TargetOverweight$160.00 ➝ $170.00Low
4/29/2020BarclaysBoost TargetOverweight$173.00 ➝ $182.00Low
4/28/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
4/28/2020Credit Suisse GroupReiterated RatingBuy$161.00Low
4/28/2020UBS GroupDowngradeBuy ➝ Neutral$163.00 ➝ $160.00Medium
4/22/2020Wells Fargo & CompanyUpgradeHoldMedium
4/22/2020Bank of AmericaUpgradeNeutral ➝ Buy$150.00 ➝ $175.00Low
4/15/2020Stifel NicolausBoost TargetHold$140.00 ➝ $155.00Medium
4/15/2020Wells Fargo & CompanyBoost TargetOverweight$150.00 ➝ $162.00Medium
4/15/2020CitigroupBoost TargetBuy$150.00 ➝ $165.00Medium
4/15/2020Raymond JamesBoost TargetOutperform$153.00 ➝ $157.00Low
4/15/2020Credit Suisse GroupBoost TargetOutperform$155.00 ➝ $161.00Low
4/9/2020Raymond JamesLower TargetOutperform$161.00 ➝ $153.00Low
4/8/2020SVB LeerinkLower TargetOutperform$172.00 ➝ $160.00High
4/3/2020Cantor FitzgeraldReiterated RatingBuy$168.00High
4/2/2020Wells Fargo & CompanyLower TargetOverweight$165.00 ➝ $150.00Medium
4/1/2020Stifel NicolausLower TargetHold$155.00 ➝ $140.00Low
3/27/2020Morgan StanleyLower TargetOverweight$170.00 ➝ $160.00Medium
3/27/2020CitigroupLower TargetBuy$163.00 ➝ $150.00Low
3/27/2020ArgusReiterated RatingBuy$165.00 ➝ $155.00Low
3/6/2020Credit Suisse GroupLower TargetOutperform$170.00 ➝ $159.00Medium
3/4/2020CitigroupInitiated CoverageBuy$163.00Low
2/17/2020Credit Suisse GroupReiterated RatingBuy$170.00Medium
1/27/2020Credit Suisse GroupBoost TargetOutperform$163.00 ➝ $170.00Low
1/23/2020Cantor FitzgeraldReiterated RatingBuy$168.00Low
1/23/2020Raymond JamesBoost TargetOutperform$147.00 ➝ $161.00Low
1/9/2020Wells Fargo & CompanyBoost TargetOverweight$155.00 ➝ $165.00Low
12/31/2019Credit Suisse GroupReiterated RatingBuy$163.00Low
12/19/2019BarclaysUpgradeEqual Weight ➝ Overweight$140.00 ➝ $173.00Medium
12/17/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$145.00 ➝ $170.00Low
11/27/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00Low
11/19/2019Cantor FitzgeraldInitiated CoverageOverweight$160.00 ➝ $160.00Low
10/24/2019Credit Suisse GroupBoost Target$158.00 ➝ $163.00Low
10/16/2019Credit Suisse GroupBoost TargetOutperform$156.00 ➝ $158.00Medium
10/16/2019Wells Fargo & CompanyLower TargetOutperform$157.00 ➝ $155.00Medium
10/16/2019Atlantic SecuritiesUpgradeUnderweight ➝ NeutralMedium
10/14/2019Raymond JamesLower TargetOutperform$146.00 ➝ $145.00Low
10/11/2019Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$155.00Low
8/27/2019The Goldman Sachs GroupSet TargetBuy$169.00Medium
8/27/2019Morgan StanleyReiterated RatingEqual Weight$145.00High
8/27/2019Credit Suisse GroupSet TargetBuy$156.00Low
7/18/2019Credit Suisse GroupSet TargetBuy$156.00Low
7/17/2019Raymond JamesLower TargetOutperform$147.00 ➝ $146.00Low
7/16/2019Royal Bank of CanadaReiterated RatingBuyLow
7/16/2019Bank of AmericaReiterated RatingHold$150.00Low
7/12/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$156.00High
6/21/2019BarclaysInitiated CoverageHold$140.00Low
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyHigh
5/16/2019Credit Suisse GroupBoost TargetOutperform$152.00 ➝ $156.00Low
5/6/2019Wells Fargo & CompanyReiterated RatingOutperform$152.00 ➝ $157.00Low
4/17/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$154.00 ➝ $157.00Low
4/17/2019Credit Suisse GroupBoost TargetOutperform ➝ Outperform$151.00 ➝ $152.00Low
4/17/2019Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$134.00 ➝ $145.00Low
4/17/2019Raymond JamesBoost TargetOutperform ➝ Outperform$145.00 ➝ $147.00Low
2/25/2019CitigroupBoost TargetNeutral ➝ Neutral$139.00 ➝ $147.00Low
1/23/2019BarclaysReiterated RatingEqual Weight ➝ Equal Weight$137.00 ➝ $135.00High
1/14/2019Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$162.00 ➝ $152.00Low
1/2/2019Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$153.00 ➝ $130.00Low
1/2/2019CitigroupLower TargetNeutral ➝ Neutral$148.00 ➝ $139.00Low
12/20/2018Morgan StanleySet TargetHold$140.00Low
10/22/2018CitigroupBoost TargetNeutral ➝ Neutral$137.00 ➝ $148.00Low
10/17/2018Credit Suisse GroupBoost TargetOutperform ➝ Outperform$149.00 ➝ $152.00Medium
10/17/2018Raymond JamesBoost TargetOutperform ➝ Outperform$144.00 ➝ $149.00Medium
10/17/2018Wells Fargo & CompanyReiterated RatingOutperform$155.00 ➝ $160.00Medium
10/17/2018HC WainwrightReiterated RatingBuyHigh
10/14/2018Credit Suisse GroupSet TargetBuy$149.00Low
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 41 very positive mentions
  • 44 positive mentions
  • 23 negative mentions
  • 16 very negative mentions
  • 32 very positive mentions
  • 25 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
  • 55 very positive mentions
  • 62 positive mentions
  • 25 negative mentions
  • 14 very negative mentions
  • 53 very positive mentions
  • 43 positive mentions
  • 10 negative mentions
  • 12 very negative mentions
  • 30 very positive mentions
  • 26 positive mentions
  • 5 negative mentions
  • 11 very negative mentions
  • 64 very positive mentions
  • 54 positive mentions
  • 8 negative mentions
  • 18 very negative mentions
  • 60 very positive mentions
  • 36 positive mentions
  • 10 negative mentions
  • 9 very negative mentions
  • 51 very positive mentions
  • 57 positive mentions
  • 13 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 51 very positive mentions
  • 57 positive mentions
  • 13 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Johnson & Johnson logo
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. This segment also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment provides products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes, and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment offers electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and contact lenses and ophthalmic technologies related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Read More

Today's Range

Now: $161.66
Low: $161.59
High: $163.49

50 Day Range

MA: $166.44
Low: $158.01
High: $174.51

52 Week Range

Now: $161.66
Low: $150.11
High: $181.04


4,526,677 shs

Average Volume

12,853,873 shs

Market Capitalization

$420.15 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Johnson & Johnson?

The following Wall Street sell-side analysts have issued research reports on Johnson & Johnson in the last twelve months: Atlantic Securities, Bank of America Co., Barclays PLC, Cantor Fitzgerald, Citigroup Inc., Credit Suisse Group AG, Guggenheim, HSBC Holdings plc, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Sanford C. Bernstein, Stifel Nicolaus,, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for JNJ.

What is the current price target for Johnson & Johnson?

17 Wall Street analysts have set twelve-month price targets for Johnson & Johnson in the last year. Their average twelve-month price target is $170.65, suggesting a possible upside of 5.6%. Cantor Fitzgerald has the highest price target set, predicting JNJ will reach $215.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $52.00 for Johnson & Johnson in the next year.
View the latest price targets for JNJ.

What is the current consensus analyst rating for Johnson & Johnson?

Johnson & Johnson currently has 9 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in JNJ, but not buy more shares or sell existing shares.
View the latest ratings for JNJ.

What other companies compete with Johnson & Johnson?

How do I contact Johnson & Johnson's investor relations team?

Johnson & Johnson's physical mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company's listed phone number is (732) 524-0400. The official website for Johnson & Johnson is Learn More about contacing Johnson & Johnson investor relations.